Rina Bandopadhyay

The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease.

Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition.

Development, characterisation and epitope mapping of novel monoclonal antibodies for DJ-1 (PARK7) protein.

Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders.

Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease.

TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing.

Differential DJ-1 gene expression in Parkinson's disease.

Pathogenesis of Parkinson's disease: emerging role of molecular chaperones.

Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model.

A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.

Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies.

Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.

Transportin1: a marker of FTLD-FUS.

α-Synuclein fate is determined by USP9X-regulated monoubiquitination.

Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.

AF-6 is a positive modulator of the PINK1/parkin pathway and is deficient in Parkinson's disease.

TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.

Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.

Inhibition of LRRK2 kinase activity stimulates macroautophagy.

Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus.

Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation.

Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.

GTP binding controls complex formation by the human ROCO protein MASL1.

Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease.

Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.

A crucial role for DOK1 in PDGF-BB-stimulated glioma cell invasion through p130Cas and Rap1 signalling.

A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.

Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistribution.

Neuropathological features of genetically confirmed DYT1 dystonia: investigating disease-specific inclusions.

Cellular processes associated with LRRK2 function and dysfunction.

LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5.

Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.